Every article, presentation, spotlight, and news item we've tagged to Testing and Diagnostics.
Your cells might be aging faster than your calendar. New epigenetic tests decode DNA methylation patterns across 900,000+ markers to reveal your true biological age—even pinpointing which organs age fastest.
Discover how epigenetic testing reveals your true biological age versus chronological age with Ryan Smith, founder of TruDiagnostic. Learn how DNA methylation patterns can predict health outcomes with 92% accuracy and track the effectiveness of longevity interventions in real-time. Smith reveals how aging is the #1 risk factor for chronic disease—10x more significant than smoking or obesity—and demonstrates how epigenetic clocks can measure biological aging from a single drop of blood, providing over 100 biomarkers to optimize your health span.
Scientists have discovered how to rebuild your cells' protective caps—telomeres—that shorten with age. New research shows telomerase activation can reduce inflammation by 62% and measurably reverse cellular aging markers.
Methylation controls over one billion cellular reactions per second, affecting everything from energy to mood to aging. Understanding your unique methylation genetics could be the missing piece in your optimization journey.
Dr. Melissa Petersen, founder of the Human Longevity Institute, demystifies epigenetics and reveals how your DNA is not your destiny—it's your potential. Through personal storytelling and accessible science, she explains methylation, biological age testing, and the concept of the longevity escape velocity. Discover how the quality of inputs—from thoughts to foods to relationships—directly communicates with your DNA, either repressing or expressing your innate potential. With her biological age at 42 despite being chronologically 52, Dr. Petersen demonstrates that aging is optional, not inevitable.
Bone density declines silently for decades before a fracture ever occurs. Radiation-free REMS technology offers a precise, accessible way to measure both bone density and microarchitecture, turning skeletal health from something abstract into something you can actively manage.
Discover the cutting-edge science behind telomeres—the protective DNA caps that determine cellular aging and lifespan. Sebastian Conti from T.A. Sciences reveals how these molecular timekeepers influence longevity and explores evidence-based strategies to support telomere health. From understanding the latest research on telomere biology to practical interventions that may slow cellular aging, this session provides actionable insights for health optimization. Learn why telomeres are considered the holy grail of aging research and how you can potentially influence your own cellular clock for enhanced healthspan and longevity.
EHE Health and Prenuvo have partnered to offer discounted whole-body MRI screening to select members, making radiation-free organ surveillance more accessible across 200+ U.S. clinics. The screening detects structural abnormalities, early-stage malignancies, and organ disease before symptom onset in under one hour.
Biological age clocks derived from DNA methylation patterns show significant day-to-day fluctuations within individuals, independent of actual chronological aging. This instability raises critical questions about their reliability for clinical application and longevity intervention assessment.
Generation Lab released SystemAge 2.1, a biological age test measuring 460+ biomarkers across 21 organ systems with sex-specific analysis and 99% validated accuracy. The platform tracks organ-level aging trajectories and quantifies treatment response to interventions including stem cells and plasma exchange, enabling practitioners to detect accelerated aging earlier and monitor intervention efficacy with precision.
Researchers have developed an interpretable epigenetic clock that maps DNA methylation patterns to specific aging pathways and disease profiles, enabling prediction of biological age and disease risk with greater mechanistic clarity. This advances the capacity to distinguish between chronological aging and disease-driven methylation changes, offering a more precise tool for identifying which physiological systems are accelerating in individual patients.
Epigenetic clocks quantify the cumulative drift in DNA methylation patterns that occurs with aging, yet their functional relationship to aging outcomes remains poorly defined. Understanding what these clocks actually measure—rather than assuming they capture aging itself—is essential for interpreting their clinical utility in longevity assessment.
Epigenetic clocks measure aging at the molecular level by tracking DNA methylation patterns and gene expression changes. Decoding these signatures reveals specific biological pathways driving accelerated aging, enabling targeted interventions before functional decline becomes apparent.
IgG glycan patterns—sugar structures attached to immune antibodies—function as modifiable biological aging markers that predict mortality risk and respond to interventions like therapeutic plasma exchange. Analysis of over 20,000 individuals across 42 studies establishes glycans as measurable indicators of immune aging that shift toward healthier profiles with targeted interventions.
Epigenetic aging clocks measure chemical changes to DNA to estimate biological age, but they are research tools designed for population-level study, not reliable for individual health assessment. Consumer products marketing these tests as personal health indicators misrepresent their validity and clinical utility.
Methylation-based epigenetic clocks demonstrate technical reliability but are vulnerable to short-term biological fluctuations that alter their outputs. This distinction between measurement consistency and biological stability has direct implications for using these clocks as aging biomarkers and intervention validators in clinical practice.
A digital twin technology modeling immune system dynamics in real time enables predictive health outcomes rather than reactive assessment. This shift from static testing to continuous simulation represents a substantive advance in personalized longevity medicine.
GlycanAge is hosting a conference with Mayo Clinic to advance clinical applications of glycan-based inflammaging markers, which can detect disease risk patterns up to a decade before symptomatic onset. The event aims to integrate chronic-inflammation testing into routine clinical practice.
Commercially available biological age tests based on epigenetic markers lack clinical validity, standardized accuracy measures, and actionable clinical utility. When physicians recommend them, they abandon evidence-based practice in favor of customer satisfaction, potentially replacing genuine health assessment with unfounded reassurance or unnecessary anxiety.
Researchers have developed Pasta, a transcriptomic clock that measures age-related changes through gene expression patterns rather than DNA methylation. This tool addresses limitations in existing epigenetic clocks by offering a more accessible method to assess how interventions affect biological aging at the molecular level.
DEXA body composition scanning has moved from clinical obscurity into mainstream longevity medicine, but rapid commercialization has created a quality control problem. Fitnescity Health's Clinical Integrity Standard addresses this by establishing voluntary benchmarks for testing environment stability, quality assurance, and clinical oversight—critical factors for reliable longitudinal tracking.
Blood protein signatures can now quantify biological aging with precision previously available only through complex genetic testing. Proteomic aging clocks measure the rate at which your body's protein landscape diverges from healthy baselines, offering a practical biomarker for assessing longevity risk and intervention responsiveness in large population studies.
IgG N-glycome patterns independently predict all-cause mortality across 20,405 individuals and respond to intervention, meeting established criteria for a valid aging biomarker. Therapeutic plasma exchange produced the largest reduction in glycan age at 0.4 years per month, positioning glycan structure as both a mechanistic link to chronic inflammation and a measurable target for lifespan extension.
Glycans—sugar molecules attached to proteins and lipids—reflect cumulative biological stress and environmental exposure in ways that precede disease symptoms by years. Unlike fixed genetic risk, glycan patterns shift with inflammation, stress, and lifestyle, offering a measurable window into trajectories of aging before clinical disease emerges.
Klotho Neurosciences has developed AI-powered genomics tests that measure biological age through DNA methylation and mRNA analysis of longevity-associated genes. This approach enables more precise stratification in clinical trials for neurodegenerative diseases, reducing confounding variables that arise when chronological and biological age diverge.
Longitudinal changes in epigenetic clocks—molecular markers of biological age—independently predict mortality over 24 years, independent of baseline biological age. This establishes that the rate of epigenetic change itself, not just absolute age status, carries clinically actionable information for longevity assessment.
Hone Health integrated clinical-grade DEXA scans into its personalized longevity platform, enabling physicians to assess body composition changes—muscle, fat, and bone density—alongside metabolic and hormonal data. This shift from reactive screening to proactive monitoring allows earlier detection of metabolic drift and interventions before functional decline.
GlycanAge's landmark conference aims to translate 25 years of inflammaging research into clinical practice by demonstrating that glycan analysis can detect disease risk up to a decade before symptoms emerge. This shift from reactive to anticipatory medicine requires both clinical validation and a fundamental change in how patients and providers interpret asymptomatic risk signals.
Hone Health integrated BodySpec DEXA scanning into its longevity platform, enabling real-time body composition, bone density, and metabolic rate assessment within clinical care plans. This shift moves bone health screening from reactive post-65 assessment to proactive longitudinal tracking across younger populations.
Superpower has integrated Galleri, a multi-cancer early detection blood test, into its preventative health platform. Data from PATHFINDER 2 showed that adding Galleri to standard screening increased cancer detection more than seven-fold, with over half of detected cancers identified at stage I or II.
Function and NYU Grossman School of Medicine are combining clinical datasets with multimodal health-monitoring data to develop AI models for earlier detection of cancer, cognitive decline, and cardiometabolic disease. This partnership represents a shift toward predictive signal detection—identifying disease markers before clinical presentation rather than after symptom onset.
